New study published in the Journal of the National Cancer Institute concludes that Epi proColon® is the test of choice for the millions of individuals not willing to participate in FIT or colonoscopy screening
BERLIN and SAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that a study published by the NCI-sponsored cancer intervention...